Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321

Watchlist Manager
Shenzhen Chipscreen Biosciences Co Ltd Logo
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Watchlist
Price: 21.53 CNY 2.72% Market Closed
Market Cap: 8.8B CNY
Have any thoughts about
Shenzhen Chipscreen Biosciences Co Ltd?
Write Note

Shenzhen Chipscreen Biosciences Co Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Chipscreen Biosciences Co Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Total Liabilities
ÂĄ1.7B
CAGR 3-Years
63%
CAGR 5-Years
49%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Liabilities
ÂĄ7.2B
CAGR 3-Years
35%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Liabilities
ÂĄ3.4B
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Liabilities
ÂĄ5.6B
CAGR 3-Years
6%
CAGR 5-Years
15%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Liabilities
ÂĄ15B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Liabilities
ÂĄ1.3B
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Chipscreen Biosciences Co Ltd
Glance View

Market Cap
8.8B CNY
Industry
Pharmaceuticals

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. The company is headquartered in Shenzhen, Guangdong and currently employs 909 full-time employees. The company went IPO on 2019-08-12. The firm focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The firm's main products include Chidamide, Siglitazone, Cioroni and CS12192. The firm mainly conducts its businesses in the domestic market.

Intrinsic Value
11.92 CNY
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Shenzhen Chipscreen Biosciences Co Ltd's Total Liabilities?
Total Liabilities
1.7B CNY

Based on the financial report for Sep 30, 2024, Shenzhen Chipscreen Biosciences Co Ltd's Total Liabilities amounts to 1.7B CNY.

What is Shenzhen Chipscreen Biosciences Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
49%

Over the last year, the Total Liabilities growth was 16%. The average annual Total Liabilities growth rates for Shenzhen Chipscreen Biosciences Co Ltd have been 63% over the past three years , 49% over the past five years .

Back to Top